ClinicalTrials.gg

Program

INI-2004

A development code.

Its studies are mostly in Rhinitis, Allergic, Perennial · Rhinitis, Allergic, led by Inimmune.

Furthest: phase 2, since Jan 15, 20262 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Inimmune20 open or runningphase 2since Jan 15, 2026Jul 31, 2023none ahead

Also a collaborator on its studies: rho-inc and avance-clinical-pty-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 31, 2023First study: phase 1 study in Rhinitis, AllergicFirst studyNCT06038279 · 68 enrolled · Australia
  2. Jan 15, 2026Phase 2 study in Rhinitis, Allergic, PerennialPhase 2 reachedNCT07556393 · 78 enrolled · Canada

TargetBeta

TLR4 →read by rule
“INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.”study text, by rule · the study

Other programs on TLR4

ProgramCompanyFurthest phaseStudies
NI-0101ruleppd-development-lpphase 34

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07556393Rhinitis, Allergic, Perennial · Canada2CompletedApr 23, 202678
NCT06038279Rhinitis, Allergic · Australia1CompletedSep 5, 202468

How it is read

Names in the registry

  • “INI-2004”, 2 entries

Codes read as this program: INI2004.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.